Sugammadex and blood loss during cervical spine fusion surgery
Copyright: © 2022 Journal of Anaesthesiology Clinical Pharmacology..
Background and Aims: Sugammadex (SUG) has been associated with changes in coagulation studies. Most reports have concluded a lack of clinical significance based on surgical blood loss with SUG use at the end of surgery. Previous reports have not measured its use intraoperatively during ongoing blood loss. Our hypothesis was that the use of SUG intraoperatively may increase bleeding.
Material and Methods: This was a single site retrospective study. Inclusion criteria were patients undergoing a primary posterior cervical spine fusion, aged over 18 years, between July 2015 and June 2021. The primary outcomes compared were intraoperative estimated blood loss (EBL) and postoperative drain output (PDO) between patients receiving SUG, neostigmine (NEO) and no NMB reversal agent. The objective was to determine if there was a difference in primary endpoints between patients administered SUG, NEO or no paralytic reversal agent. Primary endpoints were compared using analysis of variance with a P value of 0.05 used to determine statistical significance. Groups were compared using the Chi-squared test, rank sum or student's t test. A logistic regression model was constructed to account for differences between the groups.
Results: There was no difference in median EBL or PDO between groups. The use of SUG was not associated with an increase in odds for >500 milliliters (ml) of EBL. Increasing duration of surgery and chronic kidney disease were both associated with an increased risk for EBL >500 ml.
Conclusion: Intraoperative use of SUG was not associated with increased bleeding. Any coagulation laboratory abnormalities previously noted did not appear to have an associated clinical significance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of anaesthesiology, clinical pharmacology - 39(2023), 3 vom: 27. Juli, Seite 468-473 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keneally, Ryan J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 01.12.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/joacp.joacp_551_21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365167185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365167185 | ||
| 003 | DE-627 | ||
| 005 | 20231226101108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/joacp.joacp_551_21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365167185 | ||
| 035 | |a (NLM)38025572 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keneally, Ryan J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sugammadex and blood loss during cervical spine fusion surgery |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2022 Journal of Anaesthesiology Clinical Pharmacology. | ||
| 520 | |a Background and Aims: Sugammadex (SUG) has been associated with changes in coagulation studies. Most reports have concluded a lack of clinical significance based on surgical blood loss with SUG use at the end of surgery. Previous reports have not measured its use intraoperatively during ongoing blood loss. Our hypothesis was that the use of SUG intraoperatively may increase bleeding | ||
| 520 | |a Material and Methods: This was a single site retrospective study. Inclusion criteria were patients undergoing a primary posterior cervical spine fusion, aged over 18 years, between July 2015 and June 2021. The primary outcomes compared were intraoperative estimated blood loss (EBL) and postoperative drain output (PDO) between patients receiving SUG, neostigmine (NEO) and no NMB reversal agent. The objective was to determine if there was a difference in primary endpoints between patients administered SUG, NEO or no paralytic reversal agent. Primary endpoints were compared using analysis of variance with a P value of 0.05 used to determine statistical significance. Groups were compared using the Chi-squared test, rank sum or student's t test. A logistic regression model was constructed to account for differences between the groups | ||
| 520 | |a Results: There was no difference in median EBL or PDO between groups. The use of SUG was not associated with an increase in odds for >500 milliliters (ml) of EBL. Increasing duration of surgery and chronic kidney disease were both associated with an increased risk for EBL >500 ml | ||
| 520 | |a Conclusion: Intraoperative use of SUG was not associated with increased bleeding. Any coagulation laboratory abnormalities previously noted did not appear to have an associated clinical significance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Neostigmine | |
| 650 | 4 | |a neuromuscular blockade | |
| 650 | 4 | |a spinal fusion | |
| 650 | 4 | |a sugammadex | |
| 650 | 4 | |a surgical blood loss | |
| 700 | 1 | |a Lemos Lopes, Luis H |e verfasserin |4 aut | |
| 700 | 1 | |a Heekin, Mary E |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Jonathan H |e verfasserin |4 aut | |
| 700 | 1 | |a Heinz, Eric R |e verfasserin |4 aut | |
| 700 | 1 | |a Rosner, Michael K |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzeffi, Michael A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of anaesthesiology, clinical pharmacology |d 1998 |g 39(2023), 3 vom: 27. Juli, Seite 468-473 |w (DE-627)NLM094585415 |x 0970-9185 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:3 |g day:27 |g month:07 |g pages:468-473 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/joacp.joacp_551_21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 3 |b 27 |c 07 |h 468-473 | ||